Furiex Pharmaceuticals said Takeda Global Research & Development Center has resubmitted New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone ...
Tags: Furiex Pharmaceuticals, NDAs, alogliptin and pioglitazone
Novartis has planned to update the Rasilez's labelling to include contraindications against combined use with a number of products. The company will follow the advice of the EMA's Committee for Medicinal Products for Human Use (CHMP) in ...
Tags: Novartis, CHMP, Rasilez's labelling
Janssen Research & Development has submitted a new drug application (NDA) to the FDA for canagliflozin to treat adult patients with type 2 diabetes. The filing is based on a global Phase III clinical development program, including nine ...
Tags: Janssen Research&Development, SGLT2, cardiovascular study
American healthcare company Abbott has launched Perfectly Simple - a new line of nutrition bars under its ZonePerfect brand. The new bars contain ten or fewer ingredients and are a good source of protein. They are free of gluten, ...
Tags: nutrition bars, good source of protein, free of gluten
Takeda Pharmaceutical has received a complete response letter from the US Food and Drug Administration (FDA) regarding its new drug applications (NDAs) for alogliptin and the fixed-dose combination therapy alogliptin and pioglitazone. ...
Tags: FDA, alogliptin, clinical trial program
Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or a total buying price nearing $5.3bn. The acquisition value includes Amylin's debt proceeds and a contractual ...
Daiichi Sankyo has gained FDA approval to package product at its packaging facility located in Bethlehem, Pennsylvania, US. The Pennsylvania facility will package some of the company's products for cardiovascular and metabolic ...
Tags: FDA, medical product, expansion, business operations
Regeneca has issued a voluntary recall of all lots of single capsule packet RegenErect, labeled as a dietary supplement. RegenErect is a blue capsule sold individually in foil packets with a UPC code of 816860010055. The company ...
Tags: Recall, RegenErect, medical product, drug industry
A new research that analysed 235 types of rice from around the world has found that most varieties had low to medium Glycemic Index(GI),a finding which shows that rice can be part of a healthy diet for the average consumer as well those ...
Tags: rice, Glycemic Index, carbohydrates, IRRI
Pharmaceutical company in the US, Merck Sharp and Dohme (MSD) has opened a new $21m packaging facility in Pandaan, Pasuruan, Indonesia, in an effort to step up its production for the Indonesian and Asian markets. The plant, which was ...
Tags: Medicine Packaging, Pharmaceutical, packaging facility
Teva Pharmaceutical Industries has introduced an authorized generic of ACTOplus met (pioglitazone/metformin tablets) 15mg/500mg, 15mg/850mg. ACTOplus met is marketed by Takeda Pharmaceuticals USA and used with diet and exercise to improve ...
Tags: Teva Pharmaceutical Industries, pioglitazone tablets, metformin tablets
AstraZeneca and Ardelyx have signed a worldwide exclusive licensing agreement for Ardelyx's NHE3 inhibitor programme for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD). The ...
Tags: RDX5791, Ardelyx, AstraZeneca, NHE3 inhibitor programme, NHE3
Teva Pharmaceutical Industries has unveiled authorized generic of Actos (pioglitazone-hydrochloride tablets) 15mg, 30mg and 45mg in the US. Actos is marketed by Takeda Pharmaceuticals USA and used with diet and exercise to improve blood ...
The US FDA has approved Novo Nordisk Victoza (liraglutide [rDNA] injection) label to include data showing superior blood sugar control and weight reduction when compared to Januvia (sitagliptin). Label update also includes approval of ...
Tags: Label update, type 2 diabetes, Victoza
Mylan Pharmaceuticals has won final FDA approval for its abbreviated new drug application (ANDA) for Pioglitazone tablets USP, 15mg, 30mg and 45mg. Previously, FDA has also approved the company's ANDA for Pioglitazone Hydrochloride and ...